Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
2.
BMC Endocr Disord ; 23(1): 177, 2023 Aug 17.
Article in English | MEDLINE | ID: mdl-37587407

ABSTRACT

BACKGROUND: Insulin autoimmune syndrome (IAS) is a rare cause of hypoglycemia characterized by high levels of blood insulin autoantibodies. It has been documented that drugs containing sulfhydryl groups may result in IAS. In this study, we present two cases of IAS induced by methimazole, along with their corresponding treatments and a long-term follow-up after hospitalization. CASE PRESENTATION: We report two patients with Grave's disease (GD), carrying the HLA-DRB1 04:06 genotype, who experienced hypoglycemic episodes after taking methimazole. Inpatient treatments helped return their blood glucose levels to normal. Although no recurrences of hypoglycemia were present in the two cases studied, insulin autoantibodies remained positive for the previous follow-up sessions, which turned negative only three years after discharge. CONCLUSIONS: GD patients who carry the HLA-DRB1 04:06 genotype are prone to IAS if they take drugs containing sulfhydryl groups. It may take time for the elimination of insulin autoantibodies after the recovery from the hypoglycemic episode in IAS patients.


Subject(s)
Autoimmune Diseases , Graves Disease , Hyperinsulinism , Hypoglycemia , Insulins , Humans , Follow-Up Studies , Patient Discharge , HLA-DRB1 Chains/genetics , Methimazole , Autoimmune Diseases/complications , Graves Disease/complications , Graves Disease/drug therapy , Autoantibodies , Hypoglycemia/etiology , Sulfhydryl Compounds , Hypoglycemic Agents
3.
Oxid Med Cell Longev ; 2022: 8255550, 2022.
Article in English | MEDLINE | ID: mdl-35936218

ABSTRACT

Type 2 diabetes mellitus (T2DM) is a metabolic disease with increasing prevalence and mortality year by year. The purpose of this study was to explore new therapeutic targets and candidate drugs for multitargets by single-cell RNA expression profile analysis, network pharmacology, and molecular docking. Single-cell RNA expression profiling of islet ß cell samples between T2DM patients and nondiabetic controls was conducted to identify important subpopulations and the marker genes. The potential therapeutic targets of T2DM were identified by the overlap analysis of insulin-related genes and diabetes-related genes, the construction of protein-protein interaction network, and the molecular complex detection (MCODE) algorithm. The network distance method was employed to determine the potential drugs of the target. Molecular docking and molecular dynamic simulations were carried out using AutoDock Vina and Gromacs2019, respectively. Eleven cell clusters were identified by single-cell RNA sequencing (scRNA-seq) data, and three of them (C2, C8, and C10) showed significant differences between T2DM samples and normal samples. Eight genes from differential cell clusters were found from differential cell clusters to be associated with insulin activity and T2DM. The MCODE algorithm built six key subnetworks, with five of them correlating with inflammatory pathways and immune cell infiltration. Importantly, CCR5 was a gene within the key subnetworks and was differentially expressed between normal samples and T2DM samples, with the highest area under the ROC curve (AUC) of 82.5% for the diagnosis model. A total of 49 CCR5-related genes were screened, and DB05494 was identified as the most potential drug with the shortest distance to CCR5-related genes. Molecular docking illustrated that DB05494 stably bound with CCR5 (-8.0 kcal/mol) through multiple hydrogen bonds (LYS26, TYR37, TYR89, CYS178, and GLN280) and hydrophobic bonds (TRP86, PHE112, ILE198, TRP248, and TYR251). This study identified CCR5 as a potential therapeutic target and screened DB05494 as a potential drug for T2DM treatment.


Subject(s)
Diabetes Mellitus, Type 2 , Insulins , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/metabolism , Humans , Insulins/therapeutic use , Molecular Docking Simulation , Molecular Dynamics Simulation , RNA
4.
Oxid Med Cell Longev ; 2022: 3046777, 2022.
Article in English | MEDLINE | ID: mdl-35082965

ABSTRACT

Abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) are one of the main causes of the development of diabetic atherosclerotic process. The aim of our study was to assess the role of RBP4 in the proliferation and migration of VSMCs and the inhibitory effect of vitamin D on the mechanisms. In an in vivo experiment, rats were randomly classified into 6 groups: the control group, diabetic rats, diabetic atherosclerotic rats (diabetic rats intraperitoneally injected with RBP4), diabetic atherosclerotic rats treated with 0.075 µg kg-1 d-1 vitamin D, 0.15 µg kg-1 d-1 vitamin D and 0.3 µg kg-1 d-1 vitamin D. We found that the levels of JAK2, STAT3, cylinD1, and Bcl-2 were increased in diabetic atherosclerotic rats, and these increases were improved after vitamin D supplementation. Furthermore, to investigate the underlying molecular mechanisms, cells were cultured with glucose in the presence of RBP4 and the absence of RBP4, respectively, and vitamin D of different concentrations and different intervention times was simultaneously adopted. The proliferation and migration of VSMCs was enhanced and the levels of JAK2, STAT3, cyclinD1, and Bcl-2 were increased in the cells transfected with RBP4 overexpression plasmid. Moreover, vitamin D supplementation was detected to lower the expressions of JAK2, STAT3, cyclinD1, and Bcl-2 and inhibit the abnormal proliferation of VSMCs caused by the RBP4/JAK2/STAT3 signaling pathway. RBP4 can promote the proliferation and migration of VSMCs and contributes to the development of diabetic macroangiopathy via regulating the JAK2/STAT3 signaling pathway. This mechanism of RBP4 can be inhibited by vitamin D supplementation.


Subject(s)
Janus Kinase 2/metabolism , Muscle, Smooth, Vascular/metabolism , Retinol-Binding Proteins, Plasma/metabolism , STAT3 Transcription Factor/metabolism , Vitamin D/therapeutic use , Animals , Cell Movement , Cell Proliferation , Humans , Male , Rats , Rats, Wistar , Signal Transduction , Vitamin D/pharmacology
5.
Sci Bull (Beijing) ; 65(24): 2100-2106, 2020 Dec 30.
Article in English | MEDLINE | ID: mdl-36732963

ABSTRACT

The development of high-performance glucose sensors is an urgent need, especially for diabetes mellitus diagnosis. However, the glucose monitoring is conventionally operated in an invasive finger-prick manner and their noninvasive alternatives largely suffered from the relatively poor sensitivity, selectivity, and stability, resulted from the lack of robust and efficient catalysts. In this paper, we design a concave shaped nitrogen-doped carbon framework embellished with single Co site catalyst (Co SSC) by selectively controlling the etching rate on different facet of carbon substrate, which is beneficial to the diffusion and contact of analyte. The Co SSC prompts a significant improvement in the sensitivity of the solution-gated graphene transistor (SGGT) devices, with three orders of magnitude better than those of SGGT devices without catalysts. Our findings expand the field of single site catalyst in the application of biosensors, diabetes diagnostics and personalized health-care monitoring.

6.
Endokrynol Pol ; 69(3): 276-282, 2018.
Article in English | MEDLINE | ID: mdl-29952418

ABSTRACT

INTRODUCTION: The role of lipocalin 2 (LCN2) in type 2 diabetes mellitus (T2DM) needs to be fully elucidated. Moreover, bone has been demonstrated to modulate glucose metabolism via LCN2. We thus performed this study to investigate the associations of LCN2 with indexes of glucose metabolism in T2DM. The associations of LCN2 with bone metabolism were examined concurrently. MATERIAL AND METHODS: Total 288 Chinese Han subjects entered in this study including 146 patients with T2DM and 142 subjects with normal glucose tolerance. Insulin resistance was assessed by HOMA-IR and.


Subject(s)
Bone and Bones/metabolism , Collagen Type I/metabolism , Diabetes Mellitus, Type 2/metabolism , Glucose/metabolism , Lipocalin-2/blood , Aged , Asian People , Bone Density , Collagen Type I/analysis , Diabetes Mellitus, Type 2/blood , Female , Humans , Male , Middle Aged , Peptides/analysis , Peptides/metabolism
7.
Mol Med Rep ; 12(1): 520-6, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25760137

ABSTRACT

The aim of the current study was to investigate the effects and mechanism of metformin in oxidative stress and p38 mitogen-activated protein kinase (p38MAPK) expression in rat glomerular mesangial cells (MCs) cultured in a high glucose medium. Rat glomerular MCs (HBZY-1) were cultured in complete medium and divided into the following five groups: Normal control (NC), high glucose (HG), metformin-treated, SB203580-treated (SB) and N-acetylcysteine-treated (NAC). The production of intracellular reactive oxygen species (ROS) in rat glomerular MCs was measured using flow cytometry. Superoxide dismutase (SOD) activity and malondialdehyde (MDA) content in the supernatant was detected using colorimetric analysis and an ELISA, respectively. p22phox mRNA levels in rat glomerular MCs were determined using reverse transcription-quantitative polymerase chain reaction. The levels of p22phox protein and phosphorylated p38 mitogen-activated protein kinase (p-p38MAPK) protein in rat glomerular MCs were determined by western blot analysis. Compared with the NC group, the activity of SOD in the supernatant was significantly reduced, whereas the levels of MDA in the supernatant, intracellular p22phox mRNA and protein, p-p38MAPK protein in addition to ROS production in rat glomerular MCs were significantly increased in the HG group (P<0.05). When metformin was added to the high glucose medium, the activity of SOD in supernatant fluid was increased significantly, whereas a significant reduction (P<0.05) was observed in the levels of MDA in the supernatant, intracellular p22phox mRNA and protein, p-p38MAPK protein in addition to ROS production in rat glomerular MCs. These results were similar to those obtained when SB203580 or N-acetylcysteine was added to the high glucose medium (P<0.05). In conclusion, metformin was suggested to alleviate high glucose-induced oxidative stress and p-p38MAPK protein expression in rat glomerular MCs, which may contribute to its reno­protective abilities in diabetes.


Subject(s)
Diabetic Nephropathies/drug therapy , Metformin/administration & dosage , Oxidative Stress/drug effects , p38 Mitogen-Activated Protein Kinases/biosynthesis , Animals , Diabetic Nephropathies/genetics , Diabetic Nephropathies/pathology , Gene Expression Regulation/drug effects , Glucose/pharmacology , Mesangial Cells/metabolism , Mesangial Cells/pathology , Rats , Reactive Oxygen Species/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism
8.
Hum Immunol ; 75(4): 289-96, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24530745

ABSTRACT

T cells have been demonstrated to exert central roles in the development of type 2 DN (T2DN). To explore whether Th1/Th2/Th17/Treg paradigm plays an important role in the development of T2DN, we investigated the proportions of Th1/Th2/Th17/Treg cells and serum levels of relevant cytokines in T2DM patients with various degrees of nephropathy and controls. Moreover, we analyzed the relationships between the Th1/Th2/Th17/Treg paradigm or relevant cytokines with urine albumin:creatinine ratio (UACR). Our study demonstrated that the Th1/Th2/Th17/Treg paradigm skewed to Th1 and Th17 in T2DN patients. UACR was positively related to the proportions of Th1 and Th17 cells, as well as the ratio of Th17:Treg cells, and negatively related to the proportions of Treg cells. Furthermore, serum levels of IL-6, IL-17, IFN-γ, TNF-α, IL-2 and IL-10 were increased in T2DN patients, and positively related to UACR. These data indicate that the alteration of Th1/Th2/Th17/Treg paradigm exists in T2DN patients, which may contribute to the enhanced immune activation and inflammation, and subsequent development and progression of T2DN. These findings may provide one new approach to the underlying mechanisms of the development of T2DN.


Subject(s)
Diabetes Mellitus, Type 2/immunology , T-Lymphocytes, Regulatory/immunology , Th1 Cells/immunology , Th17 Cells/immunology , Th2 Cells/immunology , Aged , Albuminuria , Case-Control Studies , Creatinine/urine , Cytokines/blood , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/metabolism , Diabetic Nephropathies/etiology , Female , Glycated Hemoglobin/metabolism , Humans , Immunophenotyping , Male , Middle Aged , Risk Factors , T-Lymphocytes, Regulatory/metabolism , Th1 Cells/metabolism , Th17 Cells/metabolism , Th2 Cells/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...